Ardelyx reaches the 'capstone' in their third-straight positive PhIII – but many questions still linger
Ardelyx has added what it’s calling the topper to the mound of Phase III evidence that its lead drug can help chronic kidney disease patients, although questions remain around side effects and how great an improvement the drug offers over the standard-of-care.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
